Epigenetics Market Size Forested to be Worth over USD 61.04 Bn by 2033

According to the Vision Research Reports, the global epigenetics market size was estimated at around USD 14.65 billion in 2023 and it is forecasted to be worth over USD 61.04 billion by 2033 with a CAGR of 15.34% from 2024 to 2033. Epigenetics is the study of changes in gene expression or cellular phenotype that do not involve alterations to the underlying DNA sequence. In simpler terms, it’s the study of how external factors can influence which genes are turned on or off without changing the actual DNA sequence itself. These external factors, such as diet, stress, environmental toxins, and lifestyle choices, can affect how genes are expressed and can play a role in determining traits and disease susceptibility. Epigenetic changes can be reversible and can potentially be passed down to future generations.

Factors such as the rising prevalence of cancers, rise in funding in research and development in healthcare, and rising applications of non-oncological applications of epigenetics, among others, are expected to drive the market growth over the forecast period.

Get Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/41250

The global rise in the prevalence of cancer is one of the major factors facilitating market growth in the recent past. For instance, according to PAHO, an estimated 20 million new cancer cases and 10 million cancer deaths were estimated in 2023, and the annual reported cases of cancer are expected to reach about 30 million by 2040. The need to develop diagnostic options that can detect cancer at an early stage, which can help improve disease management & reduce mortality, is anticipated to propel the overall market growth.

As per Globocan 2020, there were 19,292,789 new cancer cases were reported worldwide. This worldwide and extensive cancer threat remains a major driver for developing new cancer therapies that help in risk assessment, early diagnosis, and effective treatment monitoring.

In addition, rising healthcare research and development expenditure across the globe is further expected to drive the growth of this market over the forecast period. For instance, according to the World Health Organization in December 2021, the gross domestic research and development expenditure on health (health GERD) as a percentage of gross domestic product (GDP) in high-income countries is 0.21%. For upper middle and low-income countries, it is 0.02%. Such huge investments in healthcare research and development will drive market growth due to adopting epigenetics in research.

On the other hand, the high cost of epigenetics and the dearth of skilled professionals in epigenetic research is expected to hamper the market studied.

Key Pointers

• Epigenetics Market size is calculated at USD 16.9 billion in 2024.
• North America led the market with the largest market share of 39% in 2023.
• Asia Pacific region is expected to grow at the notable CAGR of 16.73% from 2024 to 2033.
• By Product, the reagents segment had the largest market share of 34% in 2023.
• By Product, the services segment is anticipated to grow at the noteworthy CAGR of 17.69% from 2024 to 2033.
• By Technology, the DNA methylation segment contributed the largest market share of 46% in 2023.
• By Technology, the histone acetylation segment is expected to expand at the highest CAGR of 18.19% from 2024 to 2033.
• By Application, the oncology segment held the largest revenue share of 70% in 2023.
• By End-use, the academic research segment generated the maximum market share of 38% in 2023.
• By End-use, the clinical research segment is anticipated to grow at the noteworthy CAGR of 16.40% over the forecast period.

Immediate Delivery Available, Get Full Access@ https://www.visionresearchreports.com/report/checkout/41250

Epigenetics Market Top Trends:

• Precision Medicine Applications: Epigenetic profiling holds promise for personalized or precision medicine approaches. By analyzing the epigenome of individual patients, clinicians can better understand disease mechanisms, predict treatment response, and tailor therapies to specific patient subgroups.
• Focus on Cancer Therapeutics: Epigenetic alterations are prevalent in cancer, and targeting these changes has emerged as a promising strategy for cancer therapy. There is a growing pipeline of epigenetic drugs targeting histone modifiers, DNA methyltransferases, and other epigenetic regulators for various cancer types.
• Epigenetics in Aging and Regenerative Medicine: Epigenetic changes play a role in aging and age-related diseases, as well as in the regulation of stem cell differentiation and tissue regeneration. Research in these areas may lead to the development of interventions to promote healthy aging and tissue repair.
• Epigenetics Biomarkers for Disease Diagnosis and Prognosis: Epigenetic markers are being explored as diagnostic and prognostic biomarkers for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. These markers have the potential to improve disease detection, monitoring, and treatment decisions.
• Translational Research and Clinical Applications: There is a growing focus on translating epigenetic discoveries into clinical practice. This includes the development of epigenetic-based diagnostic tests, prognostic tools, and therapeutic interventions for improving patient outcomes and healthcare management.

Market Concentration & Characteristics

Numerous industry players are launching novel and innovative bioinformatics and computational services, which can also help revolutionize the field of epigenetics. For instance, in July 2023, FOXO Technologies Inc., a major player operating in the domain of epigenetic biomarker technology, introduced its cutting-edge Bioinformatics Services to leverage the full potential of epigenetic data by helping overcome the challenges associated with data analysis, processing, and interpretation. Such advancements are leading to a high degree of innovation in the industry.

The market is also characterized by a moderate level of merger and acquisition activities undertaken by several industry players. This is due to several factors, including the desire to gain a competitive advantage in the industry and the need to consolidate in a rapidly growing market. Some of the players undergoing mergers and acquisitions in this industry include PPD, Inc.; Arc Bio LLC; Singular Genomics Sys; and BioVision.

Regulations in the market provide a framework for the safety and quality of products but they also present challenges for industry players. The market is characterized by a high impact of regulations although the impact varies depending on the nature and stringency of regulations across geographical conditions. Furthermore, ethical and legal constraints may lead to further complexities in formulation and adherence to regulations leading to significant market challenges.

Numerous industry players are focusing on expanding their product and service portfolio. They are launching novel epigenetics services and products. For instance, in November 2023, Active Motif, the U.S.-based firm, introduced End-to-End Epigenetics Services and CUT&RUN assay kit for (cleavage under targets and release using nuclease) CUT&RUN analysis. Such product and service launches are anticipated to support the expansion of the industry’s products & services.

The industry is currently witnessing a moderate level of regional expansion, with growth prospects driven by an expanding customer base for epigenetics products & services. As scientific awareness of the technique grows globally and access to biotechnology improves in emerging markets a rise in regional expansion initiatives is expected from key players in the market.

Here’s a breakdown of how epigenetics works

• Epigenetics Definition: Epigenetics refers to changes in gene expression that occur without altering the DNA sequence itself. It involves modifications to DNA or its associated proteins that can influence gene activity.
• DNA Methylation: One of the primary mechanisms of epigenetic regulation is DNA methylation. This involves the addition of a methyl group to specific regions of DNA, typically cytosine bases within CpG dinucleotides. Methylation can either inhibit or enhance gene expression, depending on the location and context.
• Histone Modifications: Histones are proteins around which DNA is wrapped, forming chromatin. Chemical modifications, such as acetylation, methylation, phosphorylation, and ubiquitination, can occur on histone tails. These modifications alter the structure of chromatin, affecting the accessibility of DNA to transcription factors and RNA polymerase, thus regulating gene expression.
• Non-coding RNAs: Non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play crucial roles in epigenetic regulation. They can bind to target mRNAs and either inhibit their translation or promote their degradation, thereby influencing gene expression.
• Environmental Influences: Environmental factors, including diet, stress, exposure to toxins, and lifestyle choices, can impact epigenetic marks. These influences can lead to changes in gene expression patterns that may contribute to the development of various diseases or traits.
• Transgenerational Inheritance: Epigenetic modifications can be passed from one generation to the next, potentially influencing the phenotype of offspring. While the inheritance of epigenetic marks is less well understood compared to genetic inheritance, studies suggest that certain environmental exposures experienced by parents can affect the epigenome of their offspring.
• Dynamic Nature: Unlike genetic mutations, which are relatively stable, epigenetic modifications are dynamic and reversible. They can be altered in response to environmental cues, developmental stages, and cellular signals. This plasticity allows for adaptability and responsiveness to changing conditions.

Epigenetics Market Challenges:

• Complexity of Epigenetic Regulation: Epigenetic regulation is highly complex and involves multiple layers of regulation, including DNA methylation, histone modifications, and non-coding RNAs. Understanding the interplay between these different epigenetic mechanisms and their impact on gene expression presents a significant challenge.
• Standardization and Reproducibility: Variability in experimental protocols, sample processing techniques, and data analysis methods can lead to inconsistencies and challenges in reproducibility across different studies. Standardization of experimental procedures and data analysis pipelines is essential for ensuring robust and reliable results.
• Data Integration and Interpretation: Integrating and interpreting large-scale epigenomic datasets remains a challenge due to the complexity and heterogeneity of epigenetic data. Developing computational tools and bioinformatics methods for data integration, visualization, and interpretation is critical for extracting meaningful insights from epigenomic data.

Product Insights

In 2023, the reagents sector surged ahead as the dominant force in the industry, claiming 34% of global revenue. Its leading position is largely due to its widespread use in epigenetic research. Reagents are crucial in epigenetics, especially in histone and DNA modification studies. They play a vital role in understanding and manipulating the complex mechanisms of epigenetic regulation, which control changes in gene expression without altering the DNA sequence. These reagents are essential for grasping epigenetic dynamics and show promise for research and potential therapeutic applications. Notably, companies like Promega Corporation offer a wide range of reagents and kits tailored for epigenetic research, further boosting this sector’s growth.

On the other hand, the services segment is expected to see the highest compound annual growth rate (CAGR) of 17.69% during the forecast period. Epigenetic services cover various offerings, including sequencing, analysis, and consulting. Due to the intricate nature of epigenetic analyses, involving complex techniques like ChIP-seq, bisulfite sequencing, and DNA methylation profiling, many researchers and institutions turn to specialized service providers for precise and efficient execution. Additionally, the ongoing advancements in high-throughput sequencing technologies and advanced epigenetic analysis tools drive the demand for services capable of leveraging these innovations to produce comprehensive and dependable epigenomic insights.

Technology Insights

In 2023, the DNA methylation sector emerged as the dominant player, capturing a significant revenue share of 46%. DNA methylation’s prominence in epigenetics stems from its crucial role in regulating gene expression. This modification of the epigenome influences a wide array of biological processes, from development and aging to the onset and progression of diseases. Understanding the intricate patterns of DNA methylation holds significant implications for decoding complex diseases like cancer and offers promising paths for precision medicine applications. This fuels the demand for studying DNA methylation in both epigenetics research and therapeutic development.

DNA Methylation segment is expected to hold a major share in the market studied over the forecast period. DNA methylation dominated the epigenetics market, as it is the covalent addition of a methyl group in the cytosine ring, which leads to the inhibition of transcription. Sensitive bisulfite modification, followed by PCR, is called methylation-sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods, such as allele-specific bisulfite sequencing, southern-based method, bisulfite pyrosequencing, and bisulfite PCR followed by MALDI - TOF MS, are also useful for DNA methylation. Technological advancements are increasingly enabling the assessment of locus-specific DNA methylation on a genome-wide scale, thereby driving market growth.

Fundraising by the DNA methylation start-up companies is expected to drive the market growth further. For instance, in June 2020, Base Genomics, an epigenetics firm, emerged from stealth with a team of outstanding scientists and an oversubscribed seed investment round of USD 11 million USD (GBP 9 million) to further its DNA methylation technology development. Oxford Sciences Innovation led the investment round, which included investors with experience in genomics and cancer. This will lead to increased research on DNA methylation, which will further lead to the adoption of reagents, kits, and instruments for DNA methylation, driving the market growth.

In February 2021, Twist Bioscience Corporation launched the Twist NGS Methylation Detection System, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome. This will further lead to increased adoption of DNA methylation to study the human genome for research and develop novel therapies, thereby expected to drive this segment growth.

Conversely, the histone acetylation segment is set to experience the highest compound annual growth rate (CAGR) of 18.19% from 2024 to 2033. This rapid growth is attributed to the improved efficacy of the technology, thanks to the development of innovative methods. Moreover, numerous studies have highlighted the potential therapeutic advantages of histone acetylation in various disorders, including solid tumors, inflammation, leukemia, and viral infections. Consequently, the increasing recognition of histone acetylation’s therapeutic potential is expected to boost its demand and contribute to the segment’s accelerated growth in the years ahead.

Application Insights

In 2023, the oncology sector emerged as the dominant player in the market, capturing a substantial revenue share of 70%. The demand for epigenetics in oncology arises from the intricate relationship between epigenetic changes and the development of cancer. These alterations play a crucial role in assessing tumor initiation, progression, and spread. Targeting these modifications offers promising routes for innovative cancer treatments, including personalized therapies tailored to individual patients. Exploring epigenetic mechanisms in oncology holds significant potential for developing new diagnostics and more effective, personalized interventions for cancer patients, thus boosting demand in this field.

Conversely, the non-oncology segment is expected to see the fastest compound annual growth rate (CAGR) of 16.33% from 2024 to 2033. Epigenetic mechanisms are not limited to oncology but extend to a diverse range of conditions, including neurological disorders, cardiovascular diseases, metabolic disorders, autoimmune diseases, infectious diseases, rare diseases, aging, reproductive health, psychiatric disorders, drug development, precision medicine, regenerative medicine, environmental exposures, chronic inflammatory diseases, and geriatric medicine. This broad exploration of epigenetics in non-oncological applications collectively contributes to the growth and advancement of the epigenetics market, paving the way for new research avenues and therapeutic innovations across various medical fields.

End-use Insights

In 2023, the academic research sector emerged as the market leader, capturing a significant revenue share of 38%. This dominance is due to the wide-ranging implications of epigenetics across various fields, including medicine, biology, and genetics. The inherent complexity of epigenetic mechanisms offers intriguing avenues for exploration, sparking curiosity and driving academic interest. Moreover, the potential of epigenetics to shed light on mysteries surrounding diseases, development, and personalized medicine continues to stimulate growth in academic research within this domain.

On the other hand, the clinical research sector is poised to experience the fastest compound annual growth rate (CAGR) of 16.40% over the forecast period. Contract research organizations (CROs) are increasingly integrating epigenetic analyses into their research protocols because such analyses play a pivotal role in identifying and validating therapeutic targets precisely—a crucial step in the pursuit of effective treatments. Epigenetic insights offer a comprehensive understanding of how environmental factors influence gene expression, aiding in the identification of biomarkers and potential therapeutic interventions. CROs leverage these insights to improve drug efficacy assessments, predict patient responses, and streamline preclinical studies, thereby propelling growth within the clinical research segment.

Regional Insights

In 2023, North America emerged as the dominant player in the market, commanding a significant share of 39%.

The region’s growth is driven by several factors, including increased public awareness, robust medical infrastructure, and substantial investments in research and development (R&D). Moreover, the prevalence of chronic illnesses and significant investments by market players in epigenetic research further amplify regional expansion, creating a conducive environment for sustained growth. Additionally, the presence of key industry players such as Thermo Fisher Scientific, Inc., Element Biosciences, Inc., Dovetail Genomics LLC., Illumina, Inc., and Promega Corporation in the U.S. market is expected to bolster regional expansion efforts.

The factors owing to the growth include rapid developments in healthcare infrastructure, the presence of major regional players, huge investments in research and development, and the rising prevalence of cancers, among others. With increasing investments in the research and development of products by industries, the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines, are produced industrially. There is also growing demand for the development of cancer therapies in the United States, and a lot of investments are made in understanding cancer genomics, thereby expected to drive the growth of this market in North America. For instance, according to the United States National Institute of Health, in December 2021, the funding for cancer genomics was USD 1,098 million in 2020. The funding is expected to reach USD 1,152 million in 2022. The rise in funding in the United States on cancer genomics will lead to increased adoption of epigenetics in research, thereby expected to drive the market growth over the forecast period.

In addition, the rising prevalence of cancer is; also boosting the market growth in the region. For Instance, in the American Cancer Society (ACS), an estimated 1,918,030 new cases of cancer are expected for the year 2022 in the United States. Such a high burden of cancer creates the need for better diagnostics and therapeutics and hence it is expected to drive the market’s growth due to the adoption of epigenetics in cancer research.

Moreover, rising investments by the market players in the United States for developing epigenetics are further expected to drive the growth of the market studied in this region. For instance, in November 2021, Chroma Medicine, Inc. (Chroma), a new genomic medicine company pioneering epigenetic editing, launched with USD 125 million in financing to address a wide range of diseases and become the technology of choice for gene regulation.

Asia Pacific region is set to experience the fastest compound annual growth rate (CAGR) of 16.73% from 2024 to 2033. This growth trajectory is fueled by the increasing demand for genome editing technologies and the prevalence of genetic disorders and diseases across countries like India and Australia. Furthermore, domestic companies offering epigenetics products and services are attracting investments and funding, further propelling regional growth. For example, in August 2023, Epigenic Therapeutics, a China-based firm, secured USD 32 million in a Series A financing round. This company specializes in developing next-generation gene modulation therapy utilizing epigenome regulation to address prevalent disorders. The influx of investments among such industry players is expected to drive regional expansion efforts in the coming years.

Epigenetics Market Key Companies

• Roche Diagnostics
• Thermo Fisher Scientific, Inc.
• Eisai Co. Ltd.
• Novartis AG
• Element Biosciences, Inc.
• Dovetail Genomics LLC.
• Illumina, Inc.
• Promega Corporation.
• Abcam plc.

Recent Developments

• In November 2023, QIAGEN and Element Biosciences, Inc. strategically partnered to offer comprehensive Next-Generation Sequencing (NGS) workflows utilizing the innovative Element AVITI System.
• In October 2023, Zenith Epigenetics Ltd. entered into an agreement with Cencora to commercialize the ZEN-3694 program, an epigenetic approach aimed at enhancing the efficacy of cancer treatments in conjunction with existing drugs on the market.
• In September 2023, NanoString Technologies, a prominent provider of life science tools for discovery and translational research, introduced its latest GeoMx Digital Spatial Profiler (DSP) assay.

Epigenetics Market Segmentations:

By Product

• Reagents
• Kits
  • ChIP sequencing kit
  • Whole Genomic Amplification kit
  • Bisulfite Conversion kit
  • RNA sequencing kit
  • Others
• Instruments
• Enzymes
• Services

By Technology

• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large non-coding RNA
• MicroRNA modification
• Chromatin structures

By Application

• Oncology
  • Solid tumors
  • Liquid tumors
• Non-oncology oncology
  • Inflammatory diseases
  • Metabolic diseases
  • Infectious diseases
  • Cardiovascular diseases
  • Others

By End-use

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Get a Full TOC of the Report: https://www.visionresearchreports.com/epigenetics-market/41250

Immediate Delivery Available, Get Full Access@ https://www.visionresearchreports.com/report/checkout/41250

Ask here for more details sales@visionresearchreports.com OR USA: +1 650 460 3308 | IND: +91 87933 22019 | Europe: +44 2080772818